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Abstract
Background: The Fbw7 ubiquitin ligase promotes the rapid degradation of several important
oncogenes, such as cyclin E, c-Myc, c-Jun, and Notch. The two fission yeast homologs of Fbw7, pop1
and pop2, have previously been shown to dimerize. In this study, we asked whether Fbw7 can also
dimerize and how dimerization affects Fbw7 function.
Results: We found that Fbw7 binds efficiently to itself through a domain just upstream of its F-
box. We further show that dimerization is essential for the stable interaction of Fbw7 with the
cyclin E T380 phospho-degron. Surprisingly, the requirement for dimerization can be suppressed
by an additional phosphorylation of this phospho-degron at the +4 position (S384), which creates
a binding site with higher affinity for monomeric Fbw7.
Conclusion: Degradation of cyclin E by the Fbw7 pathway can, thus, be conditionally regulated
either by Fbw7 dimerization or by hyperphosphorylation of the T380 phospho-degron. Other
substrates, which cannot accommodate an extra phosphate in their phospho-degrons, or which
don't provide a negatively charged amino acid in the +4 position, may be absolutely dependent on
Fbw7 dimerization for their turnover. Our results point to an additional level of regulation for
substrate interaction and turnover by Fbw7.
Background
Fbw7 is the mammalian homolog of budding yeast CDC4
and mediates the degradation of several proteins involved
in cell growth and division, including cyclin E, c-Myc, c-
Jun, Notch, Presenilin, and SREBP [1-10]. Fbw7 recog-
nizes a phospho-epitope, termed CPD (for Cdc4 Phos-
pho-Degron), contained within these substrates. Via its F-
box, Fbw7 recruits the remainder of an SCF ubiquitin
ligase complex, thus promoting substrate ubiquitination
and rapid degradation by the proteasome [11]. Mamma-
lian cells contain three Fbw7 isoforms (Fbw7α, Fbw7β,
and Fbw7γ) that are produced by alternative splicing and
that localize to the nucleoplasm, cytoplasm, and nucleo-
lus, respectively [12-14].
Numerous cancer-associated mutations have been identi-
fied within CPDs of Fbw7 substrates that render them
insensitive to Fbw7 regulation. Accordingly, the Fbw7
gene is deleted in a large number of tumors. Moreover,
many somatic point mutations have been found that
eliminate Fbw7's function either by terminating the pro-
tein prematurely or disabling its substrate recognition
domain, the C-terminal WD40 repeats [15].
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The eight WD40 repeats form a beta-propeller structure
creating a phospho-epitope binding pocket that can rec-
ognize phosphorylated CPDs [16]. All currently known
mammalian CPDs consist of a central phosphorylated
threonine immediately followed by proline (pT-P). For
substrates like c-Myc, c-Jun, SREBP, and possibly cyclin E,
a phosphorylated serine in the +4 position serves as prim-
ing phosphate for GSK3 in order to phosphorylate the
central threonine. However, beyond simply priming for
GSK3, there appear to be additional requirements for this
negative charge in the +4 position for substrate turnover
by Fbw7.
The first evidence for this role of the +4 negative charge
came from studies of cyclin E degradation. Cyclin E's turn-
over by Fbw7 depends on the phosphorylation of T380,
the central phospho-threonine [2,3,17,18]. We previously
identified S384 as a second phosphorylation site that
plays a key role in the formation of this CPD [19,20].
However, we noticed that degradation of cyclin E by either
Fbw7β or Fbw7γ strictly required S384 phosphorylation,
whereas the requirement for this phosphorylation by
Fbw7α was depended on the stoichiometry of Fbw7α and
cyclin E. That is, high Fbw7α abundance relative to cyclin
E can overcome the need for S384 phosphorylation.
Moreover, an S384 glutamate mutant (S384E) is degraded
like wild-type cyclin E, emphasizing the importance of a
negative charge rather than a (priming) phosphate in this
position. Further evidence for a role of the +4 negative
charge was provided by the interaction between Fbw7 and
the SV40 Large T oncoprotein, which also binds to Fbw7
via a CPD and interferes with Fbw7 function [21]. Large T
contains a glutamate in the +4 position, and this residue
is crucial for its interaction with Fbw7. In fact, almost
every substrate of Fbw7 and its homologs potentially pro-
vides a negative charge in the +4 position in form of either
phosphoserine/threonine or a negatively charged gluta-
mate (Table 1) [3-5,10,17,18,21-27]. Thus, the +4 nega-
tive charge is highly conserved and likely plays a central
role in substrate regulation. Ironically, one exception to
this rule is the best-studied CDC4 substrate, Sic1, which
contains a number of imperfect CPDs that interact allova-
lently with CDC4 [16]. However, for CDC4 binding to
CPDs, the -1 and -2 positions have also been shown to be
important instead of +4, generating a slightly different
consensus: I/L-I/L/P-pTP <K/R>4 where <K/R> are disfa-
vored residues in positions +2 to +5 [11]. Although cyclin
E's T380 degron completely conforms with this consensus
we observed the additional requirement of S384 phos-
phorylation for its turnover by Fbw7.
Because the fission yeast Fbw7 homologs, pop1 and
pop2, have previously been shown to dimerize [28], we
tested whether Fbw7 can also form dimers and how
dimerization affects its functions. We identified a dimeri-
zation domain in the region common to all Fbw7 iso-
forms just upstream of the F-box. Fbw7 mutants that
cannot dimerize are fully active toward cyclin E and c-Myc
in turnover assays in cells, indicating that dimerization is
not strictly required for Fbw7 function. However, we
found that stable interactions between dimerization-defi-
cient Fbw7 and cyclin E are largely impaired and that cyc-
lin E turnover by monomeric Fbw7 completely depends
on phosphorylated S384 – even by the Fbw7α isoform.
Table 1: Alignment of CPDs.
Conservation of the negative charge in the +4 position of CPDs
0 +4 references
cyclin E: T380 LLTPPQSGK mammalian (1–3)
T62 IPTPDKEDD (3)
c-Myc : T58 LPTPPLSPS (4,5)
c-Jun: T239 GETPPLSPI (22)
SREBP 1: T456* TLTPPPSDA (10)
SV40/Large T: T701 PPTPPPEPE (21)
Notch 1: T2512* FLTPSPESP
Presenilin 1: T116 IYTPFTEDT
Gcn4: T165 LPTPVLEDA yeast (23)
Far1 : S87 PISPPPSLK (24)
Cdc6: T39 DVTPESSPE (25)
T368 PLTPTTSPV (25)
Clb6: S6 IPSPISERK (26)
T39 NLTPHSTNE (26)
Rum1 : T58 PPTPAKTPK (27)
Every CPD contains a central phospho-threonine (except of Far1 and Clb6) followed by proline and a negative charge in the +4 position (glutamate 
or phosphosite). Large T is assigned to the mammalian CPDs, because it targets Fbw7. The CPDs for Notch and Presenilin have not been published 
yet and are putative. (*) indicates the amino acid position in full-length proteins before cleavage. Exceptions to the +4 negative charge rule are most 
CPDs of Sic1, Tec1, Hap1, CDC18 and Cig2 all of which contain multiple low-affinity degrons (not shown).Cell Division 2007, 2:7 http://www.celldiv.com/content/2/1/7
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Our results link Fbw7 dimerization to the negative charge
in a CPD's +4 position and point to an additional level of
complexity in substrate turnover by Fbw7.
Results
Identification of an Fbw7 dimerization domain
In order to determine whether Fbw7 can form dimers, we
generated Flag-tagged or Myc-tagged versions of Fbw7α.
Both versions were transiently expressed in 293A cells and
immunoprecipitates from cell lysates were analyzed for
their interaction. The results demonstrated that Myc-
tagged Fbw7α efficiently co-precipitated with Flag-tagged
Fbw7α (Fig. 1A), while a truncated version of Fbw7 that
only consists of the WD40 repeats did not interact with
full length Fbw7α. Identical results were achieved in a
reciprocal immunoprecipitation (anti Myc tag) from the
same lysates (not shown). Therefore, like pop1 and pop2,
Fbw7α can dimerize. In fact, dimerization may be a more
common feature of F-box proteins, since β-TrCP has also
been shown to form dimers [29].
We then attempted to define the region on Fbw7α neces-
sary for dimerization. A panel of N-terminal truncation
mutants was constructed and tested for interaction with
full-length Fbw7α as above. This analysis revealed that a
region common to all three Fbw7 isoforms (but lacking
the isoform-specific N-terminus) was required to bind to
full-length Fbw7 (Fig. 1B). However, the M73 truncation
mutant (starting at methionine 73 of the common region)
was incapable of binding to Fbw7α, suggesting that resi-
dues upstream of M73 are essential for dimerization. Sub-
strate interaction is not required for Fbw7 dimerization,
since a cancer-associated Fbw7 point mutant that no
longer recognizes CPDs, still bound to wild-type Fbw7α
(Fig. 1B, last lane).
In order to more precisely define the dimerization
domain, we generated several additional truncation
mutants beginning just upstream of M73 and tested them
in co-immunoprecipitation assays as above. This demon-
strated that the M67 mutant (beginning at amino acid 67
of the common region) was still capable of binding to
Fbw7α, suggesting that dimerization occurs via a domain
immediately downstream of amino acid 67 (Fig. 1C). We
next generated a panel of C-terminal truncation mutants
to determine the extent of the dimerization domain. As
expected from the data shown above truncating Fbw7α at
amino acid 70 of the common region eliminated dimeri-
zation with full-length Fbw7α (Fig. 2A). Termination at
amino acid 80 also failed to enable dimerization. How-
ever, terminating Fbw7α at amino acid 90 restored stable
binding to full-length Fbw7α by about 50%, and was
completely restored at amino acid 100 of the common
region. Based on the analyses of the truncation mutants
we then generated two adjacent deletion mutants in full-
length Fbw7α just downstream of amino acid 67 (∆69–72
and ∆74–78) and tested them for dimerization defects.
Figure 2B clearly demonstrates that both mutants are
severely impaired with regards to dimerization. The
dimerization of an additional deletion mutant lacking
amino acids 82 to 87 was also largely compromised (not
shown). We conclude that Fbw7 dimerizes via an
extended domain between amino acids 67 and at least 90
of the common region (see model, Fig. 2C).
Because we mapped the dimerization domain to the com-
mon region of Fbw7, we asked whether Fbw7β and Fbw7γ
also homodimerize, and whether the different isoforms
heterodimerize. Myc- and Flag-tagged versions of all three
Fbw7 isoforms were analyzed for their interactions by co-
immunoprecipitation. As expected both the Fbw7β and
Fbw7γ isoforms could homodimerize (Fig. 3A). Interest-
ingly, there was a clear preference for homo- over het-
erodimerization, most likely reflecting the differing sub-
cellular localization of each isoform. Furthermore, some
isoforms were able to form heterodimers, at least when
overexpressed in 293A cells. Since vast overexpression can
lead to leaking of the Fbw7 isoforms into different subcel-
lular compartments, we repeated this experiment using 5-
fold lower amounts of plasmid DNA. This demonstrated
a more pronounced tendency for homo- over het-
erodimerization, in particular for cytoplasmic Fbw7β (Fig.
3B). However, nuclear Fbw7α and nucleolar Fbw7γ were
still able to interact efficiently under these conditions.
Fbw7 dimerization in cells
In order to determine whether heterodimerization may be
a post-lysis artifact or actually occurs in cells, we analyzed
these interactions by immunofluorescence of fixed cells.
U2OS cells were grown on coverslips and transfected with
each individual Flag-tagged Fbw7 isoform either alone or
together with Myc-tagged Fbw7 isoforms in every het-
erodimeric combination. The localization of Flag-tagged
Fbw7 was then assayed by immunofluorescence. As
shown in figure 3C, co-expression of the nucleoplasmic
Fbw7α protein caused the normally nucleolar Fbw7γ pro-
tein to become mislocalized to the nucleoplasm suggest-
ing that they interact in cells, and this was dependent on
an intact dimerization domain of Fbw7α. In contrast, co-
expression of cytoplasmic Fbw7β did not relocalize
Fbw7γ. Consistent with the preference for homodimeriza-
tion observed in figures 3A and 3B, Fbw7α and Fbw7β
were largely unaffected by co-expressing any other iso-
form (not shown).
We also attempted to examine homodimerization with
this assay. To this end, we made use of our previously
described localization mutants that place both Fbw7α
and Fbw7γ into the cytoplasm due to deletion of their
nuclear localization signals (NLS)[13]. Remarkably, co-Cell Division 2007, 2:7 http://www.celldiv.com/content/2/1/7
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Mapping of the Fbw7 dimerization domain (1) Figure 1
Mapping of the Fbw7 dimerization domain (1). A: Fbw7α can form dimers. Flag- and Myc-tagged versions of Fbw7α as 
well as the Flag-tagged WD40 domain were transfected in 293A cells as indicated and analyzed for their interaction by immu-
noprecipitation with Flag antibody. Co-precipitated Myc-tagged Fbw7α was detected with 9E10 antibody (upper panel). The 
membrane was subsequently re-probed with Flag antibody (lower panel). Flag-Fbw7α corresponds to the lower band, Myc-
Fbw7α to the upper band. The asterisk indicates the heavy chain of the Flag antibody used for immunoprecipitation. B: Analysis 
of N-terminal truncation mutants. Myc-tagged Fbw7α was co-expressed with Flag-tagged Fbw7α or various N-terminal trunca-
tion mutants as well as a point mutant of Fbw7α that no longer interacts with CPDs. Lysates were immunoprecipitated with 
Flag antibody and probed as indicated. ∆N refers to an N-terminal-less Fbw7 construct corresponding to the common region 
of Fbw7. All amino acid numbers reflect positions within the common region. The truncation mutants are depicted at the bot-
tom. C: Fine-tuning of the dimerization domain beginning. The assay is similar as in A. The asterisk indicates the heavy chain of 
the Flag antibody used for immunoprecipitation.Cell Division 2007, 2:7 http://www.celldiv.com/content/2/1/7
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Mapping of the Fbw7 dimerization domain (2) Figure 2
Mapping of the Fbw7 dimerization domain (2). A: Analysis of C-terminal truncation mutants. Fbw7α was terminated 
after 70, 80, 90, and 100 amino acids of the common region (schematic below) and assayed as in A. The 9E10 blot (for detec-
tion of Myc-tagged Fbw7α) was subsequently probed with Flag antibody. B: Short deletion mutants eliminate dimerization. 
Same assay, except that two short deletion mutants were tested for their binding to full length Myc-tagged Fbw7α. The amino 
acid numbering of the deletions in full-length Flag-Fbw7α again corresponds to their positions in the common region. C: Sche-
matic of Fbw7 splice forms including their WD40 repeats, F-box, and dimerization domain.Cell Division 2007, 2:7 http://www.celldiv.com/content/2/1/7
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Fbw7 isoforms interact in cells (1) Figure 3
Fbw7 isoforms interact in cells (1). A: Homo- and heterodimerization of Fbw7. Differentially tagged Fbw7 isoforms were 
transfected as indicated and lysates subjected to immunoprecipitations with Flag antibody. B: Fbw7α and Fbw7γ heterodimer-
ize. Identical assay as in A, except 5-fold lower amounts of each isoform were expressed. C: Heterodimerization of Fbw7α and 
Fbw7γ occurs in cells. U2OS cells grown on cover slips were co-transfected with Flag-Fbw7γ and Myc-tagged versions of either 
Fbw7α, the Fbw7α dimerization mutant, or Fbw7β. Cover slips were fixed and co-stained with Flag and Myc antibodies.Cell Division 2007, 2:7 http://www.celldiv.com/content/2/1/7
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expression of Fbw7α relocalized both NLS mutants into
the nucleoplasm in a dimerization-dependent fashion,
clearly demonstrating their ability to interact with one
another in situ (Fig. 4). These experiments were also per-
formed in 293A cells with similar results (not shown).
Taken together, all three Fbw7 isoforms can homo- and
partially heterodimerize in intact cells, at least when
expressed ectopically. This observation may have implica-
tions for the general compartmentalization of the endog-
enous Fbw7 isoforms (see discussion).
Dimerization is not strictly required for Fbw7 function
We next tested whether Fbw7 dimerization mutants are
capable of promoting cyclin E and c-Myc turnover. Cyclin
E and CDK2 were co-expressed with either wild-type
Fbw7α or dimerization mutants in 293A cells and steady-
state levels of cyclin E were analyzed by western blotting.
As shown in figure 5A, both the non-dimerizing deletion
mutant (∆74–78) and the M73 truncation mutant were
able to degrade cyclin E similar to wild-type Fbw7. We did
not observe any significant impairment of the dimeriza-
tion mutant compared to wild-type Fbw7α, even upon
titration of either cyclin E or Fbw7 (Fig. 5B and 5C).
Dimerization-defective Fbw7 also promoted c-Myc turno-
ver (Fig. 5D) and bound well to SV40 Large T (not shown
and [21]). Therefore, at least in these types of assays, Fbw7
dimerization is not strictly required for substrate degrada-
tion.
Conditional requirement for Fbw7 dimers
The requirement for S384 phosphorylation in cyclin E
turnover by Fbw7α is conditional and depends upon
Fbw7 stoichiometry [20]. We therefore tested whether
S384 manipulation would affect cyclin E's binding and
turnover by Fbw7 dimerization mutants. Wild-type cyclin
E or S384 mutants changed to alanine or glutamate were
expressed in 293A cells together with either Fbw7α or the
dimerization mutant. Steady-state abundance of cyclin E
was then analyzed by western blotting. Figure 6A demon-
strates that wild-type cyclin E and the S384E mutant are
both efficiently degraded by Fbw7α and by the dimeriza-
tion mutant. As expected, Fbw7α was also able to elimi-
nate the S384A mutant at this stoichiometry. However,
the S384A mutant was completely resistant to non-dimer-
izing Fbw7α (Fig. 6A), and this was independent of the
stoichiometry between the S384A and Fbw7 mutants (not
shown).
In addition to its potential priming role for GSK3, S384
phosphorylation participates in the formation of the T380
CPD and is likely to mediate direct contacts with Fbw7
[19]. We therefore directly tested the role of Fbw7 dimer-
ization in binding to cyclin E and the S384 mutants by co-
immunoprecipitation. In order to capture this transient
interaction we co-expressed a dominant-negative version
of Cul1, an essential core component of SCF complexes,
in an otherwise identical experiment as in figure 6A. This
prevents cyclin E ubiquitination and degradation and
allows stable binding of cyclin E to Fbw7 [20]. Lysates
were immunoprecipitated against Fbw7α or the dimeriza-
tion mutant and western blotted for co-immunoprecipi-
tated cyclin E (Fig. 6B). The results confirmed that the
stable interaction between the S384A mutant and Fbw7α
is largely impaired compared with wild-type cyclin E. This
is not simply due to decreased T380 phosphorylation of
this mutant (see lysate). In fact, the extent of T380 phos-
phorylation is comparable between the S384A and S384E
mutants, yet only S384E is efficiently bound to Fbw7. This
supports the notion that a negative charge in +4 directly
contributes to Fbw7 binding.
Dimerization-deficient Fbw7α, on the other hand, was
partly compromised in binding to wild-type cyclin E and
completely lost its ability to interact with the S384A
mutant (Fig. 6B), even on very long exposures (not
shown). Surprisingly, S384E failed to restore efficient
binding to the Fbw7α dimerization mutant despite the
finding that the S384E mutant is degraded by monomeric
Fbw7 (compare Figs. 6A and 6B). The reason for this dis-
crepancy is unclear, but probably reflects differences in
contact formations of phospho-serine versus glutamate
with the WD40 repeats of Fbw7. The implications of our
findings are summarized in figure 7.
Discussion
We have shown that human Fbw7 can form dimers and
mapped the dimerization domain to a region just
upstream of the F-box. Since this domain is preserved in
all Fbw7 splice variants, Fbw7 may, in principle, be able
to form both homo- and heterodimers. However, we and
others have demonstrated previously that the Fbw7 iso-
forms localize to distinct subcellular compartments
[12,13,20]. Due to the absence of suitable antibodies, all
Fbw7 localization studies relied on overexpressed tagged
Fbw7, and all conclusions were drawn from the expres-
sion of a single Fbw7 isoform at a time. Here we show
that, at least upon co-overexpression, some isoforms can
interact in cells and alter their localization through het-
erodimerization. This suggests that, in addition to the cis-
acting signals that normally direct them to their locations,
the stoichiometry of the endogenous Fbw7 isoforms and
the extent of heterodimerization may influence their com-
partmentalization. It is unclear to what extent (het-
ero)dimerization among the endogenous Fbw7 isoforms
occurs. Due to their low abundance, we are currently una-
ble to detect the endogenous Fbw7 proteins and are
restricted to studying ectopically expressed Fbw7. One
intriguing consequence of heterodimerization is that one
Fbw7 isoform may be able to regulate the activity of
another isoform by directing it to another cellular address.Cell Division 2007, 2:7 http://www.celldiv.com/content/2/1/7
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Fbw7 isoforms interact in cells (2) Figure 4
Fbw7 isoforms interact in cells (2). Cytoplasmic versions of Fbw7α (A) and Fbw7γ (B) lacking their according nuclear 
localization signals (NLS) were co-expressed with Myc-tagged Fbw7α or the dimerization mutant and cover slips co-stained 
with Flag and Myc antibodies. All images in are representatives of at least three independent experiments and were also carried 
out in 293A cells (not shown).Cell Division 2007, 2:7 http://www.celldiv.com/content/2/1/7
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Monomeric Fbw7 is active Figure 5
Monomeric Fbw7 is active. A: Turnover of cyclin E by dimerization mutants of Fbw7. 293A cells were transfected either 
with active cyclin E (wild-type CDK2) or inactive cyclin E (dominant-negative CDK2) together with various versions of Fbw7 as 
indicated. Steady-state protein abundance of cyclin E was monitored by immunoblotting (upper panel). The same membrane 
was subsequently blotted for Fbw7 and CDK2 (middle panel). The asterisks mark cross-reactions from the 12CA-5 antibody 
used to detect HA-tagged CDK2. A shorter exposure of CDK2 was chosen and is shown in the lower panel. B: Cyclin E turn-
over at altered Fbw7 stoichiometry. 0.5 µg of cyclin E plasmid was co-expressed with titrated amounts of either wild-type or 
dimerization-deficient Fbw7α (3, 1, 0.3, and 0.1 µg, respectively) and blotted for steady-state protein abundance as indicated. 
C: Cyclin E turnover by Fbw7 at altered stoichiometry. 2 µg of Fbw7 plasmid or the non-dimerizing mutant were co-expressed 
with increasing amounts of cyclin E (0.5, 1, 2, and 4 µg) and protein levels analyzed as above. In both experiments 2 µg of 
CDK2 were co-expressed (not shown). D: Fbw7 dimerization is not required for c-Myc degradation. c-Myc and Fbw7 trunca-
tion mutants were co-transfected as indicated and their protein levels analyzed by western blotting. ∆N refers to N-terminal-
less Fbw7 and corresponds to the common region of Fbw7. All truncation mutants start at the indicated methionines within 
the common region. The M158 mutant no longer contains the F-box and is therefore inactive.Cell Division 2007, 2:7 http://www.celldiv.com/content/2/1/7
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For instance, the extent of heterodimerization between
Fbw7α and Fbw7γ may regulate the amount of nucleolar
Fbw7γ and, hence, the activities of nucleolar substrates.
Besides potentially affecting isoform localization, dimeri-
zation may directly regulate other functional aspects of
Fbw7. For instance, since the dimerization domain is
adjacent to the F-box, we initially tested the idea that
dimerization may prevent the interaction with Skp1 and,
hence, inactivate Fbw7. However, we found no evidence
for this, since Skp1 bound indistinguishably to mono-
meric and dimerized Fbw7 (not shown). Instead, we
uncovered a requirement of Fbw7 dimerization for the
regulation of certain substrates. Our results establish a
link between Fbw7 dimerization and the presence of a
negative charge in the +4 position of cyclin E's T380-CPD.
The implications of our findings suggest differential
modes of action by Fbw7 and sub-divide Fbw7 targets
into three groups. First are substrates that always provide
the negative charge in +4 via glutamates, aspartates, or
constitutive (priming) phosphorylation. This subgroup
may not rely on Fbw7 dimerization for their turnover. Sec-
A role for Fbw7 dimerization Figure 6
A role for Fbw7 dimerization. A: Dimerization-deficient Fbw7 strictly requires S384 phosphorylation for cyclin E turnover. 
Cyclin E/CDK2 or two S384 mutants of cyclin E (S384A and S384E) were co-transfected into 293A cells together with either 
wild-type or non-dimerizing Fbw7α as indicated. Lysates were probed for the steady-state expression of these proteins with an 
antibody cocktail. The asterisks indicate cross-reactions. B: Analysis of stable interaction between cyclin E and Fbw7α. 293A 
cells were transfected as indicated together with dominant-negative Cul1. Binding of Fbw7α to cyclin E was assayed by co-
immunoprecipitation anti Flag. dnCul1 co-migrates with the Flag antibody heavy chain. The asterisks indicate heavy chain cross-
reactions. The upper panel lysate membrane was incubated with a cocktail of antibodies to detect all relevant proteins.Cell Division 2007, 2:7 http://www.celldiv.com/content/2/1/7
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Model for role of Fbw7α dimerization Figure 7
Model for role of Fbw7α dimerization. A: Cdk2 (S384) and GSK3 (T380) prime cyclin E for destruction. The hyper-phos-
phorylated T380/S384 degron has high affinity for monomeric Fbw7α, which engages the remainder of the SCF to initiate cyclin 
E's ubiquitination by an E2 enzyme (B). C: Hypo-phosphorylated cyclin E that lacks S384 phosphorylation within the T380 
phospho-degron can still be degraded by Fbw7α. However, this destruction pathway requires Fbw7 dimerization. Dimerization 
recruits a second E2 ubiquitin conjugating enzyme (E2) that may help elongating the same ubiquitin chain or may initiate 
another chain. Alternatively, the second Fbw7α component of the dimer may actually contact another degron within cyclin E, 
possibly the T62 degron, and may help stabilizing the substrate interaction.Cell Division 2007, 2:7 http://www.celldiv.com/content/2/1/7
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ond are substrates that sometimes, perhaps conditionally,
provide this charge and may switch their CPD affinity in
response to environmental cues. Cyclin E is an example of
this group and can be degraded independent of Fbw7
dimerization when S384 is phosphorylated, but becomes
dependent on S384 phosphorylation for monomeric
Fbw7 (see model in figure 7). Also c-Myc may belong to
this subgroup, since it has been suggested that S62
became de-phosphorylated after having served as primer
for T58 phosphorylation [30]. However, in our assays c-
Myc regulation by Fbw7 is not dependent on Fbw7 dimers
(Fig. 5D). Finally, some substrates may never provide this
charge and therefore are completely dependent on Fbw7
dimerization for their degradation. Such CPDs probably
mediate weaker interactions with Fbw7 and may entirely
rely on cooperative effects together with other (weak)
CPDs. The activities of these substrates may in part be con-
trolled by the state of Fbw7 dimerization and are possibly
subjected to an additional level of regulation, if dimeriza-
tion itself was controlled.
Sic1 requires at least six phosphorylated CPDs for optimal
destruction by CDC4, each of which are flawed by the
absence of the +4 negative charge, the presence of non-
favorable basic amino acids, or both [11,16]. Therefore,
the low-affinity CPDs of Sic1, like cyclin E that is not
phosphorylated on S384, may entirely depend on CDC4
dimerization for efficient turnover. Indeed, recent studies
have shown that Sic1 degradation requires CDC4 dimeri-
zation (Mike Tyers personal communication). Why low
affinity CPDs require F-box protein dimerization remains
unclear, but perhaps their affinity is so low that the
recruitment of several SCF complexes is required for effi-
cient substrate degradation. Dimerized Fbw7 (or CDC4)
may simply be twice as efficient in substrate ubiquitina-
tion, because two SCF complexes can recruit two E2 ubiq-
uitin ligases, and this may be necessary for the turnover of
low-affinity substrates.
Several mechanistic ideas arise from our observations.
One possibility is that dimerized Fbw7 binds to two dif-
ferent CPDs concurrently to increase substrate affinity and
facilitate more efficient ubiquitination of its substrate.
This model would be a plausible explanation to account
for the more transient interactions of Fbw7/CDC4 with
low-affinity CPDs and is depicted in figure 7D. Alterna-
tively, a dimer may bind to a single CPD via one of the
dimer moieties while the other one simply recruits a sec-
ond E2 enzyme, perhaps for more efficient ubiquitination
(Figure 7C). Moreover, a dimerized SCF might elongate
the same ubiquitin chain, act on two different chains, or
perhaps several dimers elongate one single ubiquitin
chain when bound to different CPDs. All of these models
may apply in a substrate-specific fashion or even for dif-
ferent CPDs within the same substrate.
Conclusion
Our results suggest that Fbw7's affinity for certain sub-
strates underlies yet another level of regulation that links
the negatively charged +4 position of CPDs and Fbw7's
ability to form dimers. We propose that weak CPDs that
do not contain the + 4 charge must either cooperate with
another (weak?) CPD or bring a second SCF to the same
low-affinity CPD for efficient substrate destruction via
Fbw7 dimerization.
Methods
Cell culture, transfections, plasmids
U2OS (human osteosarcoma) and HEK-293A (human
embryonic kidney) cell lines were cultured under stand-
ard conditions in DMEM containing 10% FCS. For tran-
sient transfections experiments, cells were seeded into 6
cm dishes and transfected the next day by Ca-precipitation
overnight at 30 to 40% confluence. 24 hrs after washing
and replacing the media cells were harvested either for
protein extracts or immunostaining. Typically, we express
1/10 of the plasmid amount of pFlag-Fbw7α (0.3 µg)
compared to Fbw7β and Fbw7γ (3 µg each). The in vivo
Fbw7-driven cyclin E turnover assay was performed as
described [19]. All point mutants and deletions were
introduced by the Quick Change method (Stratagene)
and confirmed by sequencing. The deletions ∆69–72 and
∆74–78 correspond to amino acids EWLK and FQSWS,
respectively. Truncation mutants were generated by PCR
and sequenced. All amino acid numbers indicate their
positions within the common region of Fbw7.
Immunofluorescence, immunoprecipitation, 
immunoblotting
For immunofluorescence, cells were seeded and trans-
fected on glass coverslips. Slips were fixed with ice-cold
Methanol/Acetone (1:1) for 5 min, air-dried and immu-
nostained with primary antibody. After washing with PBS,
slips were incubated with secondary FITC-coupled anti-
mouse antibody, washed, dried and mounted. For double
stainings mouse Flag-tag and rabbit Myc-tag antibodies
were mixed and visualized with FITC- and dopamine-cou-
pled secondary antibodies. All protein extracts were made
with Tween 20 lysis buffer [19]. Protein expression was
determined by standard procedures (SDS-PAGE, western
blot, immunoblot). Protein complexes were analyzed by
immunoprecipitation. The following primary antibodies
were used in this study: anti-Flag for Fbw7 (Sigma, M2),
anti-HA for CDK2 and dnCul1 (12CA-5), anti-c-Myc
(Santa Cruz, sc-N262), anti-Myc-tag for cyclin E and Fbw7
(9E-10 and Cell Signaling #2278), anti-pT380 for phos-
pho-cyclin E (Santa Cruz, sc-12917-R).
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